Baotou, China
Baotou, China

Time filter

Source Type

Zhang Q.,Baotou Cancer Hospital | Shi B.,Baotou Cancer Hospital | Liu Z.,Baotou Cancer Hospital | Zhang M.,Baotou Cancer Hospital | Zhang W.,Beijing Institute of Technology
OncoTargets and Therapy | Year: 2013

Background: This study used CT (computed tomography) and magnetic resonance imaging (MRI) to identify correlations between perfusion parameters for squamous cell lung carcinoma and tumor angiogenesis in a rabbit model of VX2 lung cancer. Methods: VX2 tumors were implanted in the lungs of 35 New Zealand White rabbits. CT and MRI perfusion scanning were performed on days 14, 17, 21, 25, and 28 after tumor implantation. CT perfusion parameters were perfusion, peak enhanced increment, transit time peak, and blood volume, and MRI perfusion parameters were wash in rate, wash out rate, maximum enhancement rate, and transit time peak. CT and MRI perfusion parameters were obtained at the tumor rim, in the tumor tissue, and in the muscle tissue surrounding the tumor. Results: On CT perfusion imaging, t values for perfusion, peak enhanced increment, and blood volume (tumor rim versus muscle) were 16.31, 11.79, and 5.21, respectively (P, 0.01); t values for perfusion, peak enhanced increment, and blood volume (tumor versus muscle) were 9.87, 4.09, and 5.35, respectively (P, 0.01); and t values for transit time peak were 1.52 (tumor rim versus muscle) and 1.29 (tumor versus muscle), respectively (P. 0.05). On MRI perfusion imaging, t values for wash in rate, wash out rate, and maximum enhancement rate (tumor rim versus muscle) were 18.14, 8.79, and 6.02, respectively (P, 0.01); t values for muscle wash in rate, wash out rate, and maximum enhancement rate (tumor versus muscle) were 9.45, 8.23, and 4.21, respectively (P, 0.01); and t values for transit time peak were 1.21 (tumor rim versus muscle) and 1.05 (tumor versus muscle), respectively (P. 0.05). Conclusion: A combination of CT and MRI perfusion imaging demonstrated hemodynamic changes in a rabbit model of VX2 lung cancer, and provides a theoretical foundation for treatment of human squamous cell lung carcinoma. © 2013 Zhang et al, publisher and licensee Dove Medical Press Ltd.


PubMed | University of Houston, Tianjin Medical University and Baotou Cancer Hospital
Type: Journal Article | Journal: Oncotarget | Year: 2016

To investigate the effects of mTOR inhibition on drug resistance in lung adenocarcinoma after combined radiation and erlotinib therapy.Combined radiation and erlotinib therapy produced clear radiosensitization effects both in vitro and in vivo; however, tumor cells remained drug resistant. Additionally, combined radiation and erlotinib therapy significantly increased p-AKT and p-P70 levels. After mTOR inhibition, the number of surviving cells significantly decreased compared with that before inhibition, and the in vivo growth curve was significantly reduced.The effects of combined radiation and erlotinib therapy on tumor inhibition and drug resistance were evaluated by in vitro survival curves in PC9 lung adenocarcinoma cell line and in vivo growth curves in nude mouse xenograft tumor model respectively. The association between tumor drug resistance and the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K-AKT-mTOR) pathway was measured by western blot, assessing the changes in protein kinase B (AKT), phosphor-AKT (p-AKT), P70, and p-P70 protein levels. MTOR was inhibited using everolimus, and changes in AKT, p-AKT, P70, and p-P70 levels were observed. Furthermore, changes in in vitro survival curves, and in vivo growth curves before and after mTOR inhibition were evaluated to confirm its effects on drug resistance in lung adenocarcinoma after combined radiation and TKI therapy.mTOR was associated with drug resistance in lung adenocarcinoma after radiation combined with TKI, and MTOR inhibition reversed drug resistance in lung adenocarcinoma after combined radiation and TKI therapy.


PubMed | Inner Mongolia University, Chongqing Medical University and Baotou Cancer Hospital
Type: Journal Article | Journal: Molecular medicine reports | Year: 2016

Xlinked inhibitor of apoptosis (XIAP)associated factor1 (XAF1), a tumor suppressor, is downregulated in most human malignant tumors. However, the tumor suppressive role of XAF1 in hepatocellular carcinoma (HCC) and its therapeutic value require further elucidation. The present study examined the expression of XAF1 at the mRNA and protein level in the HCC and paired peritumor tissue specimens, as well as in HCC cell lines and a normal liver cell line. A recombinant adenovirus which coexpressed XAF1 and TNF was then constructed, and its effects on the proliferation and colony formation ability of the MHCC97H HCC cell line were assessed using apoptosis induction, flow cytometry, trypan blue staining assay and a clonogenic assay. The results demonstrated that the expression of XAF1 was significantly reduced in HCC tissues compared with that in their matched peritumor specimens, and a significant correlation with the tumor size, stage and tumornodesmetastasis stage was identified. The reduced levels of XAF1 were further confirmed the HCC cell lines MHCC97L, HepG2 and MHCC97H compared with those in the L02 normal liver cell line. The recombinant adenovirus AdXAF1&TNF, which coexpressed XAF1 and TNF, was shown to efficiently express the two proteins at the mRNA and protein level. Furthermore, infection with AdXAF1&TNF synergistically induced apoptosis, reduced the proliferation and colony formation ability of MHCC97L cells to a significantly greater extent than overexpression of XAF1 or TNF individually. To the best of our knowledge, the present study was the first to construct an adenovirus which coexpressed XAF1 and TNF in the same open reading frame and expressed them proportionally. As AdXAF1&TNF inhibited HCC cells with enhanced efficiency, it may be applicable for the treatment of HCC.


Li X.-F.,Baotou Cancer Hospital | Guo X.-G.,Baotou Cancer Hospital | Yang Y.-Y.,Baotou Cancer Hospital | Liu A.-Y.,Baotou Cancer Hospital
Asian Pacific Journal of Cancer Prevention | Year: 2015

Background: To explore the relationship between CXCR4, CD133 co-expression and clinicopathological features as well as prognosis of patients with phase II~III colon cancer. Materials and Methods: Forty-nine paraffin-embedded samples of tumor tissue and epithelial tissue adjacent to cancer were collected from patients with colon cancer undergoing radical surgery in Baotou Cancer Hospital from January, 2010 to June, 2011. CXCR4 and CD133 expression was detected using immunohistochemistry and its relationship with clinicopathological features and the 3-year survival rate was analyzed. Results: In the tumor tissue and colonic epithelial tissue adjacent to cancer, the positive expression rates of CXCR4 were respectively 61.2% (30/49) and 8.16% (4/49), while those of CD133 being 36.7% (18/49) and 6.12% (3/49). CXCR4 and CD133 expression in tumor tissue was not related to patient age, gender, primary focal sites, tumor size, TNM staging, histological type, tumor infiltration depth and presence or absence of lymphatic metastasis, but CXCR4 and CD133 co-expression was associated with TNM staging and lymphatic metastasis. The 3-year survival rate of patients with CXCR4 and CD133 co-expression was 27.3% (3/11), and that of the remainderwas 76.3% (29/38), the difference being significant (χ2=7.0206, p=0.0081). Conclusions: CXCR4 and CD133 co-expression may be a risk factor for poor prognosis of patients with stage II~III colon cancer.


Li K.,Chongqing Medical University | Li K.,Baotou Cancer Hospital | Guo X.,Baotou Cancer Hospital | Wang Z.,Chongqing Medical University | And 5 more authors.
OncoTargets and Therapy | Year: 2016

Increased aldehyde dehydrogenase 1 (ALDH1) activity has been determined to be present in the stem cells of several kinds of cancers including gastric cancer (GC). Nevertheless, which ones of ALDH1’s isoenzymes are leading to ALDH1 activity remains elusive. In this study, we examined the prognostic value and hazard ratio (HR) of individual ALDH1 isoenzymes in patients with GC using “The Kaplan-Meier plotter” database. mRNA high expression level of ALDH1A1 was not found to be significantly correlated with the overall survival (OS) of all patients with GC followed for 20 years, HR =0.86 (95% confidence interval [CI]: 0.7-1.05), P=0.13. mRNA high expression level of ALDH1A2 was also not significantly correlated with OS for all patients with GC, HR =1.13 (95% CI: 0.91-1.41), P=0.25. mRNA high expression level of ALDH1A3 was found to be significantly correlated with worsened OS in either intestinal-type patients, HR =2.24 (95% CI: 1.44-3.49), P=0.00026, or diffuse-type patients, HR =1.91 (95% CI: 1.02-3.59), P=0.04. Interestingly, mRNA high expression level of ALDH1B1 was found to be significantly correlated with better OS for all patients with GC, HR =0.66 (95% CI: 0.53-0.81), P=7.8e-05, and mRNA high expression level of ALDH1L1 was found to be significantly correlated with worsened OS for all patients with GC, HR =1.23 (95% CI: 1-1.51), P=0.048. Furthermore, our results also indicate that ALDH1A3 and ALDH1L1 are potential major contributors to the ALDH1 activity in GC, since mRNA high expression levels of ALDH1A3 and ALDH1L1 were found to be significantly correlated with worsened OS for all patients with GC. Based on our study, ALDH1A3 and ALDH1L1 are potential prognostic markers and therapeutic targets for patients with GC. © 2016 Li et al.


Li X.,Baotou Cancer Hospital | Zhao X.-X.,Baotou Cancer Hospital | Xu F.,Baotou Cancer Hospital
Journal of Practical Oncology | Year: 2011

Objective: To evaluate the safety and efficacy of transurethral plasma cutting operation (TURis-Bt) in treatment of bladder carcinoma. Methods: The clinical data of 101 cases of bladder carcinoma invading muscular layer were retrospectively analyzed. Fifty-four patients underwent transurethral plasma cutting operation, among whom 50 were followed-up for 24-60 months. Forty-seven patients were treated with partial bladder resection and followedup for 1-60 months. Both groups received bladder instiUation of pirarubicin (THP). Results: The recurrence rate of TURis-Bt group was 29.6% (16/54), while that of partial bladder resection group was 29.8% (14/47). There was no significant difference between two groups. Conclusion: TURis-Bt can be used to treat bladder carcinoma invading muscular layer, especially for high-risk patients or patients who are unwilling to accept open surgery.


Wang H.-M.,Baotou Cancer Hospital | Zhou S.,Baotou Cancer Hospital | Wang W.,Baotou Cancer Hospital
World Chinese Journal of Digestology | Year: 2014

Aim: To analyze the incidence trends and characteristics of colorectal cancer in Inner Mongolia urban and rural areas.Methods: According to colorectal cancer incidence database derived from Inner Mongolia tumor registries from 2009 to 2013, there were a total population of 24706321 (including both urban and rural areas). ICD-9 and ICD-0-3 were used in the registries. Incidence trends were analyzed using the percentage change and the annual percent change (APC).Results: From 2009 to 2013, colorectal cancer incidence was 29.18/105 in Inner Mongolia, with 33.42/105 and 14.55/105 observed in urban and rural areas, respectively. The adjusted incidence rate in the Chinese standards was 22.98/105. From 2009 to 2013, colorectal cancer incidence increased by 18.93% (18.91% in urban areas and 10.84% in rural areas).Conclusion: Colorectal cancer incidence rate in rural areas in China is lower than that in urban areas. An increasing incidence rate was observed in rural areas in contrast to the decreasing trend in urban areas. © 2014 Baishideng Publishing Group Inc. All rights reserved.


PubMed | Baotou Cancer Hospital
Type: Journal Article | Journal: Molecular and clinical oncology | Year: 2014

The present study aimed to investigate the correlation of the of hemoglobin A1c (HbA1c), C-peptide and insulin-like growth factor-1 (IGF-1) levels with the development and progression of lung cancer. The serum HbA1c, C-peptide and IGF-1 levels were measured and compared between 80 lung cancer patients and 80 healthy controls; furthermore, their correlation with histopathological type and tumor stage was analyzed in the 80 lung cancer patients. Our results suggested that the levels of HbA1c, C-peptide and IGF-1 were significantly increased in patients with lung cancer compared to those in the control group (P<0.05). In addition, the levels of C-peptide and IGF-1 were significantly higher in the small-cell lung cancer group (n=18), the stage III-IV (n=55) group and the lung cancer with diabetes mellitus group (n=43) compared to those in the non-small-cell lung cancer group (n=62), the stage I-II lung cancer group (n=25) and the lung cancer without diabetes group (n=37), respectively (P<0.05). Thus, the present study suggests that the increased serum HbA1c, C-peptide and IGF-1 levels are significantly correlated with the development and progression of lung cancer.


This study used CT (computed tomography) and magnetic resonance imaging (MRI) to identify correlations between perfusion parameters for squamous cell lung carcinoma and tumor angiogenesis in a rabbit model of VX2 lung cancer.VX2 tumors were implanted in the lungs of 35 New Zealand White rabbits. CT and MRI perfusion scanning were performed on days 14, 17, 21, 25, and 28 after tumor implantation. CT perfusion parameters were perfusion, peak enhanced increment, transit time peak, and blood volume, and MRI perfusion parameters were wash in rate, wash out rate, maximum enhancement rate, and transit time peak. CT and MRI perfusion parameters were obtained at the tumor rim, in the tumor tissue, and in the muscle tissue surrounding the tumor.On CT perfusion imaging, t values for perfusion, peak enhanced increment, and blood volume (tumor rim versus muscle) were 16.31, 11.79, and 5.21, respectively (P < 0.01); t values for perfusion, peak enhanced increment, and blood volume (tumor versus muscle) were 9.87, 4.09, and 5.35, respectively (P < 0.01); and t values for transit time peak were 1.52 (tumor rim versus muscle) and 1.29 (tumor versus muscle), respectively (P > 0.05). On MRI perfusion imaging, t values for wash in rate, wash out rate, and maximum enhancement rate (tumor rim versus muscle) were 18.14, 8.79, and 6.02, respectively (P < 0.01); t values for muscle wash in rate, wash out rate, and maximum enhancement rate (tumor versus muscle) were 9.45, 8.23, and 4.21, respectively (P < 0.01); and t values for transit time peak were 1.21 (tumor rim versus muscle) and 1.05 (tumor versus muscle), respectively (P > 0.05).A combination of CT and MRI perfusion imaging demonstrated hemodynamic changes in a rabbit model of VX2 lung cancer, and provides a theoretical foundation for treatment of human squamous cell lung carcinoma.


PubMed | Baotou Cancer Hospital
Type: Journal Article | Journal: Asian Pacific journal of cancer prevention : APJCP | Year: 2015

To explore the relationship between CXCR4, CD133 co-expression and clinicopathological features as well as prognosis of patients with phase II~III colon cancer.Forty-nine paraffin-embedded samples of tumor tissue and epithelial tissue adjacent to cancer were collected from patients with colon cancer undergoing radical surgery in Baotou Cancer Hospital from January, 2010 to June, 2011. CXCR4 and CD133 expression was detected using immunohistochemistry and its relationship with clinicopathological features and the 3-year survival rate was analyzed.In the tumor tissue and colonic epithelial tissue adjacent to cancer, the positive expression rates of CXCR4 were respectively 61.2% (30/49) and 8.16% (4/49), while those of CD133 being 36.7% (18/49) and 6.12% (3/49). CXCR4 and CD133 expression in tumor tissue was not related to patient age, gender, primary focal sites, tumor size, TNM staging, histological type, tumor infiltration depth and presence or absence of lymphatic metastasis, but CXCR4 and CD133 co-expression was associated with TNM staging and lymphatic metastasis. The 3-year survival rate of patients with CXCR4 and CD133 co-expression was 27.3% (3/11), and that of the remainderwas 76.3% (29/38), the difference being significant (2=7.0206, p=0.0081).CXCR4 and CD133 co-expression may be a risk factor for poor prognosis of patients with stage II~III colon cancer.

Loading Baotou Cancer Hospital collaborators
Loading Baotou Cancer Hospital collaborators